These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 9871937)

  • 1. [Comparative activity of cefepime, ceftazidime and imipenem in a mouse infection caused by Klebsiella pneumoniae producing a broad spectrum beta-lactamase].
    Ronco E; Lawrence C; Nauciel C
    Pathol Biol (Paris); 1998 Oct; 46(8):651-5. PubMed ID: 9871937
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activity of cefepime and carbapenems in experimental pneumonia caused by porin-deficient Klebsiella pneumoniae producing FOX-5 beta-lactamase.
    Pichardo C; del Carmen Conejo M; Bernabéu-Wittel M; Pascual A; Jiménez-Mejías ME; de Cueto M; Pachón-Ibáñez ME; García I; Pachón J; Martínez-Martínez L
    Clin Microbiol Infect; 2005 Jan; 11(1):31-8. PubMed ID: 15649301
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro and in vivo activities of amikacin, cefepime, amikacin plus cefepime, and imipenem against an SHV-5 extended-spectrum beta-lactamase-producing Klebsiella pneumoniae strain.
    Szabó D; Máthé A; Filetóth Z; Anderlik P; Rókusz L; Rozgonyi F
    Antimicrob Agents Chemother; 2001 Apr; 45(4):1287-91. PubMed ID: 11257049
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of cefepime and imipenem in experimental murine pneumonia caused by porin-deficient Klebsiella pneumoniae producing CMY-2 beta-Lactamase.
    Pichardo C; Rodríguez-Martínez JM; Pachón-Ibañez ME; Conejo C; Ibáñez-Martínez J; Martínez-Martínez L; Pachón J; Pascual A
    Antimicrob Agents Chemother; 2005 Aug; 49(8):3311-6. PubMed ID: 16048941
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of porins and plasmid-mediated AmpC beta-lactamases on the efficacy of beta-lactams in rat pneumonia caused by Klebsiella pneumoniae.
    Padilla E; Alonso D; Doménech-Sánchez A; Gomez C; Pérez JL; Albertí S; Borrell N
    Antimicrob Agents Chemother; 2006 Jun; 50(6):2258-60. PubMed ID: 16723600
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Efficacies of ceftazidime and cefepime in rats with experimental pneumonia caused by extended-spectrum beta-lactamase-producing strain of Klebsiella pneumonia].
    Wang WF; Liu YN; She DY
    Zhonghua Jie He He Hu Xi Za Zhi; 2006 Jun; 29(6):390-4. PubMed ID: 17045021
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacies of piperacillin-tazobactam and cefepime in rats with experimental intra-abdominal abscesses due to an extended-spectrum beta-lactamase-producing strain of Klebsiella pneumoniae.
    Thauvin-Eliopoulos C; Tripodi MF; Moellering RC; Eliopoulos GM
    Antimicrob Agents Chemother; 1997 May; 41(5):1053-7. PubMed ID: 9145868
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro activity of avibactam (NXL104) in combination with β-lactams against Gram-negative bacteria, including OXA-48 β-lactamase-producing Klebsiella pneumoniae.
    Aktaş Z; Kayacan C; Oncul O
    Int J Antimicrob Agents; 2012 Jan; 39(1):86-9. PubMed ID: 22041508
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Detection of multiresistant ceftazidime-susceptible Klebsiella pneumoniae isolates lacking TEM-26 after class restriction of cephalosporins.
    Urban C; Mariano N; Rahman N; Queenan AM; Montenegro D; Bush K; Rahal JJ
    Microb Drug Resist; 2000; 6(4):297-303. PubMed ID: 11272258
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Failure of cefepime therapy in treatment of Klebsiella pneumoniae bacteremia.
    Song W; Moland ES; Hanson ND; Lewis JS; Jorgensen JH; Thomson KS
    J Clin Microbiol; 2005 Sep; 43(9):4891-4. PubMed ID: 16145169
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of cefepime for the treatment of infections caused by extended spectrum beta-lactamase-producing Klebsiella pneumoniae and Escherichia coli.
    Labombardi VJ; Rojtman A; Tran K
    Diagn Microbiol Infect Dis; 2006 Nov; 56(3):313-5. PubMed ID: 17084784
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cefepime and the inoculum effect in tests with Klebsiella pneumoniae producing plasmid-mediated AmpC-type beta-lactamase.
    Kang CI; Pai H; Kim SH; Kim HB; Kim EC; Oh MD; Choe KW
    J Antimicrob Chemother; 2004 Dec; 54(6):1130-3. PubMed ID: 15486080
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Trends in Susceptibility Rates and Extended-Spectrum β-Lactamase Production of Klebsiella pneumoniae in Bloodstream Infections Across the United States Veterans Affairs Healthcare System.
    Gentry CA; Williams RJ
    Microb Drug Resist; 2015 Dec; 21(6):590-9. PubMed ID: 26207392
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The effect of cefepime on ceftazidime, cefotaxime and imipenem resistant strains of Acinetobacter, Xanthomonas, Pseudomonas, Flavobacterium, Sphingobacterium and on producers of extended spectrum beta-lactamases (ESBL) with resistance transfer].
    Blahová J; Hupková-Lesická M; Králiková K; Krcméry V; Kubonová K
    Cas Lek Cesk; 1997 Mar; 136(5):154-6. PubMed ID: 9221190
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Laboratory identification, risk factors, and clinical outcomes of patients with bacteremia due to Escherichia coli and Klebsiella pneumoniae producing extended-spectrum and AmpC type β-lactamases.
    Tsui K; Wong SS; Lin LC; Tsai CR; Chen LC; Huang CH
    J Microbiol Immunol Infect; 2012 Jun; 45(3):193-9. PubMed ID: 22580086
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of cefepime for the treatment of infections caused by extended spectrum: beta-lactamase-producing Klebsiella pneumoniae and Escherichia coli.
    Arya SC; Agarwal N; Solanki BS; Agarwal S
    Singapore Med J; 2007 Jun; 48(6):600-1. PubMed ID: 17538771
    [No Abstract]   [Full Text] [Related]  

  • 17. Diagnosis and treatment of extended-spectrum and AmpC beta-lactamase-producing organisms.
    Yang K; Guglielmo BJ
    Ann Pharmacother; 2007 Sep; 41(9):1427-35. PubMed ID: 17666573
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro killing of parenteral beta-lactams against standard and high inocula of extended-spectrum beta-lactamase and non-ESBL producing Klebsiella pneumoniae.
    Burgess DS; Hall RG
    Diagn Microbiol Infect Dis; 2004 May; 49(1):41-6. PubMed ID: 15135499
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and Pharmacokinetics of the Combination of OP0595 and Cefepime in a Mouse Model of Pneumonia Caused by Extended-Spectrum-Beta-Lactamase-Producing Klebsiella pneumoniae.
    Kaku N; Kosai K; Takeda K; Uno N; Morinaga Y; Hasegawa H; Miyazaki T; Izumikawa K; Mukae H; Yanagihara K
    Antimicrob Agents Chemother; 2017 Jul; 61(7):. PubMed ID: 28507106
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nosocomial spread of ceftazidime-resistant Klebsiella pneumoniae strains producing a novel class a beta-lactamase, GES-3, in a neonatal intensive care unit in Japan.
    Wachino J; Doi Y; Yamane K; Shibata N; Yagi T; Kubota T; Ito H; Arakawa Y
    Antimicrob Agents Chemother; 2004 Jun; 48(6):1960-7. PubMed ID: 15155185
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.